385 related articles for article (PubMed ID: 38402232)
1. Challenges and strategies associated with CAR-T cell therapy in blood malignancies.
Liu Z; Lei W; Wang H; Liu X; Fu R
Exp Hematol Oncol; 2024 Feb; 13(1):22. PubMed ID: 38402232
[TBL] [Abstract][Full Text] [Related]
2. Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches.
Gu T; Zhu M; Huang H; Hu Y
J Zhejiang Univ Sci B; 2022 Oct; 23(10):793-811. PubMed ID: 36226535
[TBL] [Abstract][Full Text] [Related]
3. Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: Coupling active strategies to overcome therapeutic limitations.
Wang L
Curr Res Transl Med; 2022 Jan; 70(1):103320. PubMed ID: 34768218
[TBL] [Abstract][Full Text] [Related]
4. Resistance and recurrence of malignancies after CAR-T cell therapy.
Zeng W; Zhang P
Exp Cell Res; 2022 Jan; 410(2):112971. PubMed ID: 34906583
[TBL] [Abstract][Full Text] [Related]
5. Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies.
Xie D; Jin X; Sun R; Zhang M; Wang J; Xiong X; Zhang X; Zhao M
Technol Cancer Res Treat; 2022; 21():15330338221118413. PubMed ID: 35989682
[TBL] [Abstract][Full Text] [Related]
6. CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies.
Huang J; Huang X; Huang J
Front Immunol; 2022; 13():1019115. PubMed ID: 36248810
[TBL] [Abstract][Full Text] [Related]
7. Potential strategies against resistance to CAR T-cell therapy in haematological malignancies.
Cai Q; Zhang M; Li Z
Ther Adv Med Oncol; 2020; 12():1758835920962963. PubMed ID: 33133242
[TBL] [Abstract][Full Text] [Related]
8. Current status of CAR-T cell therapy for pediatric hematologic malignancies.
Hiramatsu H
Int J Clin Oncol; 2023 Jun; 28(6):729-735. PubMed ID: 37154980
[TBL] [Abstract][Full Text] [Related]
9. CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?
Khan AN; Asija S; Pendhari J; Purwar R
Eur J Haematol; 2024 Jan; 112(1):6-18. PubMed ID: 37545253
[TBL] [Abstract][Full Text] [Related]
10. The Role of Chimeric Antigen Receptor-T Cell Therapy in the Treatment of Hematological Malignancies: Advantages, Trials, and Tribulations, and the Road Ahead.
Rohit Reddy S; Llukmani A; Hashim A; Haddad DR; Patel DS; Ahmad F; Abu Sneineh M; Gordon DK
Cureus; 2021 Feb; 13(2):e13552. PubMed ID: 33815972
[TBL] [Abstract][Full Text] [Related]
11. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.
Zhang X; Zhu L; Zhang H; Chen S; Xiao Y
Front Immunol; 2022; 13():927153. PubMed ID: 35757715
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies.
Nie Y; Lu W; Chen D; Tu H; Guo Z; Zhou X; Li M; Tu S; Li Y
Biomark Res; 2020; 8():18. PubMed ID: 32514351
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of Resistance to Chimeric Antigen Receptor T Cell Therapy.
Johnson GA; Locke FL
Hematol Oncol Clin North Am; 2023 Dec; 37(6):1189-1199. PubMed ID: 37580193
[TBL] [Abstract][Full Text] [Related]
14. The journey of CAR-T therapy in hematological malignancies.
Lu J; Jiang G
Mol Cancer; 2022 Oct; 21(1):194. PubMed ID: 36209106
[TBL] [Abstract][Full Text] [Related]
15. Bispecific CAR T-cells for B-cell Malignancies.
Furqan F; Shah NN
Expert Opin Biol Ther; 2022 Aug; 22(8):1005-1015. PubMed ID: 35653589
[TBL] [Abstract][Full Text] [Related]
16. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple Myeloma.
Rejeski K; Jain MD; Smith EL
Transplant Cell Ther; 2023 Jul; 29(7):418-428. PubMed ID: 37076102
[TBL] [Abstract][Full Text] [Related]
18. Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes.
Roselli E; Faramand R; Davila ML
J Clin Invest; 2021 Jan; 131(2):. PubMed ID: 33463538
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.
Ho M; Zanwar S; Paludo J
Eur J Haematol; 2024 Feb; 112(2):197-210. PubMed ID: 37545132
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
